Affiliation:
1. Department of Infectious Diseases Austin Health Heidelberg Victoria Australia
2. National Centre for Infections in Cancer Peter MacCallum Cancer Centre Parkville Victoria Australia
3. Department of Pharmacy Austin Health Heidelberg Victoria Australia
4. Department of Medicine University of Melbourne Melbourne Victoria Australia
5. Department of Clinical Haematology Austin Health Heidelberg Victoria Australia
Abstract
SummaryThe co‐administration of venetoclax, a BCL‐2 inhibitor, with a mould‐active azole, such a posaconazole, has potential to both prevent invasive fungal infection (IFI) and reduce the required treatment dose, and cost, of venetoclax. Posaconazole drug‐level monitoring is critical to ensuring adequate mould prophylaxis. A retrospective audit of 99 patients at a tertiary cancer centre, with myeloid malignancies co‐prescribed venetoclax and posaconazole between January 2018 and April 2022, was undertaken to evaluate the adequacy of posaconazole prescribing and the rate of breakthrough IFI. Seventy‐six patients (77%) had at least one posaconazole level measured in the study period, with 37% requiring a dose adjustment based on steady‐state trough levels. Breakthrough IFI occurred in 4% of patients, typically within 1 month of commencing anti‐mould prophylaxis. Close monitoring of posaconazole levels in venetoclax‐treated patients, particularly in the early, outpatient setting, is critical.
Funder
National Health and Medical Research Council
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献